|
The FDA on Dec. 12 granted
an accelerated approval to Mirati Therapeutics’ Krazati for
the treatment of KRAS G12C-mutated locally advanced or metastatic non-small
cell lung cancer (NSCLC) in patients that have received at least one other
systemic therapy. The KRAS inhibitor, Mirati’s first commercial product, will
face off against Amgen’s blockbuster-hopeful Lumakras, which gained approval
in May 2021. Lumakras was the first KRAS inhibitor on the market, and
currently holds covered or better status for 94% of all insured lives under
the pharmacy benefit for the treatment of KRAS-mutated NSCLC. About 15.5% of
covered lives have preferred access to Lumakras. |
|
SOURCE: MMIT Analytics,
as of 12/14/22 |
No comments:
Post a Comment